Agoracom Blog Home

Archive for the ‘Quantum BioPharma Ltd.’ Category

« Older Entries

Quantum BioPharma Cuts Liabilities in Half, Boosts Equity 275%, and Strengthens Path to Phase 2 MS Trial

Posted by Brittany McNabb at 12:09 PM on Tuesday, November 11th, 2025

Quantum BioPharma Ltd. (NASDAQ/CSE: QNTM; FRA: 0K91) today reported a strong third quarter, marking continued progress across both financial and scientific fronts. The biopharmaceutical company, focused on developing innovative treatments for neurodegenerative, metabolic, and alcohol-related conditions, demonstrated clear operational discipline while advancing its clinical and consumer health initiatives.

Financial Turnaround Anchored by Balance-Sheet Strength

Quantum BioPharma delivered significant quarter-over-quarter improvement, underscoring the company’s strengthened financial foundation. Shareholder equity increased 275%, while the debt-to-equity ratio improved by 86%, driven largely by the full elimination of liabilities related to previously issued convertible debentures.

Total liabilities declined from US $13.2 million to US $6.6 million, and general and administrative expenses were reduced by 8%. Liquidity improved substantially, with the current ratio rising to 1.41x from 0.78x in the prior quarter. Collectively, these results reaffirm the company’s “no going concern” position and extend its cash runway beyond March 2027.

Quantum also realized US $572,000 in gains from its digital-asset portfolio, primarily Bitcoin, as part of a diversified treasury strategy. As of September 30, 2025, the company held US $5.2 million in digital assets, up from US $0.8 million at year-end 2024, further enhancing its financial flexibility.

Lucid-MS: Advancing a New Approach to Multiple Sclerosis

At the core of Quantum’s R&D pipeline is Lucid-21-302 (Lucid-MS), a patented, first-in-class oral drug candidate designed to target the underlying biology of demyelination — the process that drives nerve-fiber damage in Multiple Sclerosis (MS).

The company recently completed 3- and 6-month oral toxicity studies that showed no toxicity or adverse side effects, a key milestone supporting advancement toward a Phase 2 human efficacy trial. Lucid-MS’s oral formulation offers a convenient alternative to existing MS therapies that require injections or infusions.

Quantum has also partnered with Massachusetts General Hospital (MGH) researchers in a joint PET imaging study to validate a new approach for monitoring myelin integrity in MS patients. In parallel, the company has engaged a global pharmaceutical development organization to prepare an Investigational New Drug (IND) submission to the U.S. FDA.

“Lucid-MS represents a new direction in MS treatment — one focused on protecting myelin and addressing the biological drivers of neurodegeneration,” said Zeeshan Saeed, President and Chief Executive Officer.

Expanding Consumer Health and Diversified Assets

Beyond its pharmaceutical programs, Quantum continues to expand its portfolio of commercially active consumer health assets.

Its licensed product unbuzzd™, designed to accelerate alcohol metabolism and ease hangover symptoms, is marketed in the United States by Unbuzzd Wellness Inc. The licensee launched powder stick packs in late 2024 and has since initiated a Reg D  financing of up to US $5 million in preparation for a potential initial public offering — without any equity dilution to Quantum.

In Canada, Health Canada has granted a Product License for Qlarity™, a natural-health formulation that supports energy, metabolism, and cognitive performance. Qlarity™ complements Quantum’s broader focus on neurological health and wellness.

Sustained Progress and Long-Term Vision

The third quarter also saw continued progress in Quantum’s efforts to address alleged market manipulation of its stock. Management confirmed that all hedge-fund-held warrants have now expired, and that a special dividend of Contingent Value Rights (CVRs) was distributed to Class B shareholders in October 2025.

Looking ahead, Quantum BioPharma plans to maintain disciplined financial management while advancing its clinical and consumer-health milestones. The company’s balance-sheet strength, diversified portfolio, and advancing MS program collectively establish a foundation for sustained growth in 2026 and beyond.

With a Phase 2 trial for Lucid-MS approaching and a global consumer-health pipeline expanding, Quantum BioPharma remains positioned at the intersection of biotechnology innovation, financial resilience, and long-term therapeutic impact.

Visit $QNTM HUB On AGORACOM :https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM:https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

 

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

 

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews/video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

Tags: , , , ,
Posted in AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, AGORACOM Traffic, All Recent Posts, Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma Cuts Liabilities in Half, Boosts Equity 275%, and Strengthens Path to Phase 2 MS Trial

Quantum BioPharma Launches USD $7 Million Reward Program for Proof of Market Manipulation

Posted by Brittany McNabb at 3:58 PM on Friday, October 31st, 2025

Quantum BioPharma (NASDAQ/CSE: QNTM) has formally launched a public whistleblower reward program, offering up to USD $7 million to any individual or entity who can provide definitive, verifiable evidence that they were asked, hired, or induced to manipulate the Company’s stock.

This initiative is directly tied to Quantum’s ongoing landmark litigation, which alleges multi-year market manipulation and seeks damages exceeding USD $700 million.

✅ Anonymous submissions are accepted
✅ Confidentiality will be protected to the fullest extent permitted by law
✅ This program does NOT replace SEC or Canadian regulatory whistleblower programs — individuals may qualify for BOTH

How to Submit Information (Direct & Confidential)

[email protected]

Ineligible to Apply

  • Current officers, directors, or employees of Quantum BioPharma
  • Government officials/regulators acting in official capacity
  • Anyone who obtained information illegally or in violation of duty
  • Anyone submitting false or fabricated information

Important Legal Clarification

Rewards are not guaranteed and will only be paid if the submitted information materially contributes to a final, non-appealable legal judgment or binding settlement in the Company’s favor.

Quantum will not use any information provided until compensation terms are agreed to in writing with the whistleblower.

For full program details and FAQ, visit: QuantumBioPharma.com
This statement is issued in the interest of market integrity and shareholder protection.

Disclaimer

This Reward Program is discretionary and subject to change or withdrawal at any time without notice. Reward eligibility does not depend on whether a whistleblower testifies, awards are based on the contribution and reliability of the information. Quantum Biopharma will not direct, script, or influence any witness testimony. Rewards are not payments for testimony. Payment of any reward is contingent upon legal review, Board approval, and the successful outcome of a final, non‑appealable judgment or binding settlement of ongoing or future litigation pursued by the Quantum BioPharma at trial to which the reported information materially contributes. Nothing in this FAQ creates a contractual right to payment. This program does not replace, restrict or limit rights under the U.S. Securities and Exchange Commission (SEC) Whistleblower Program or whistleblower programs operated by Canadian regulatory authorities, and individuals remain free to report directly to the SEC and Canadian regulatory authorities.

 

Tags: , , , ,
Posted in AGORACOM Sector Spotlight, Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma Launches USD $7 Million Reward Program for Proof of Market Manipulation

The Critical Role of the Myelin Sheath – And How Quantum BioPharma Is Advancing the Next Frontier in MS Neuroprotection

Posted by Brittany McNabb at 3:39 PM on Wednesday, October 29th, 2025

Quantum BioPharma (NASDAQ/CSE: QNTM) is advancing a novel therapeutic approach to Multiple Sclerosis (MS) — one centered not on suppressing the immune system, but on targeting the underlying biology of demyelination, the core driver of neurodegeneration in MS. To understand why this approach matters, it’s critical to understand the role of the myelin sheath.

What Is the Myelin Sheath and Why Does It Matter?

The myelin sheath is a fatty, insulating layer that wraps around nerve cell axons — acting like the high-speed wiring system of the nervous system. It is produced by specialized glial cells: oligodendrocytes in the central nervous system (CNS) and Schwann cells in the peripheral nervous system.

Myelin’s value comes from four critical functions:

  • Insulation: Prevents electrical “leaks” in signal transmission
  • Speed: Enables saltatory conduction — signals “jump” node to node (up to 100× faster)
  • Efficiency: Reduces the energy neurons need to fire signals
  • System control: Supports cognition, movement, perception, and coordination

Without myelin, the electrical messages between brain and body slow, weaken, or misfire — leading to the symptoms widely associated with neurological disorders like MS.

What Happens in Multiple Sclerosis

In MS, the myelin sheath is progressively damaged — historically thought to be caused only by immune system attack. However, leading researchers now point to a second process at play: a degenerative component that occurs independently of immune activity.

Both pathways lead to demyelination — the loss or disruption of the myelin sheath — resulting in impaired communication between neurons.

This degradation is what produces the hallmark symptoms of MS:

  • Loss of motor coordination
  • Impaired sensory perception
  • Declining cognitive function
  • Fatigue and loss of balance

Quantum BioPharma’s Approach: Precision Neuroprotection

Unlike conventional immunosuppressive MS treatments, Lucid-MS – Quantum’s patented lead drug candidate — is not immunomodulatory.

Instead, it is designed to address demyelination at the biological level, advancing a neuroprotective strategy that could complement, rather than compete with, existing immune-focused treatments.

Lucid-MS has completed successful Phase 1 human safety trials, with no serious adverse events reported. Multiple animal studies have demonstrated significant activity relevant to demyelination biology, providing additional confidence as Quantum advances toward a Phase 2 clinical trial in people with MS.

A Thoughtful, Science-Driven Evolution in MS Treatment Strategy

The global MS treatment market is heavily concentrated on slowing immune system attack. Quantum BioPharma is moving deeper — focusing on the root mechanisms of nerve damage itself.

Its approach signals an evolution in neuroscience:

  • From suppression → to protection 
  • From reaction → to resilience 
  • From slowing disease → to targeting its biological engine 

Looking Ahead

Quantum BioPharma is positioning Lucid-MS within the growing global focus on regenerative and neuroprotective medicine. As regulatory preparation accelerates, the company continues to emphasize precision science, data integrity, and clinical depth — not speculation.

For official clinical progress updates, visit: www.QuantumBioPharma.com

Visit $QNTM HUB On AGORACOM :https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM:https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

 

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews/video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

 

Tags: , , , , , ,
Posted in AGORACOM Sector Spotlight, All Recent Posts, Quantum BioPharma Ltd. | Comments Off on The Critical Role of the Myelin Sheath – And How Quantum BioPharma Is Advancing the Next Frontier in MS Neuroprotection

Quantum BioPharma’s Year of Execution: Clinical Momentum, Platform Progress, and a Stronger Balance Sheet

Posted by Brittany McNabb at 4:19 PM on Monday, August 18th, 2025

Advancing a Novel Approach to Multiple Sclerosis

Quantum BioPharma Ltd. (NASDAQ: QNTM; CSE: QNTM) is advancing therapies for challenging neurological and related conditions with a lead focus on multiple sclerosis (MS). Its flagship program, Lucid-MS (Lucid-21-302), is a patented, non-immunomodulatory compound designed to protect myelin—the insulating sheath around nerve fibers that is damaged in MS. Unlike many approved MS drugs that primarily suppress immune activity, Lucid-MS targets neuroprotection and myelin integrity, a differentiated strategy supported by preclinical data showing prevention of demyelination and reversal of paralysis.

From First-in-Human to Phase 2 Readiness

The program progressed through first-in-human testing with a Phase 1 multiple-ascending-dose (MAD) trial in healthy adults. The Clinical Study Report (CSR) concluded no safety or tolerability concerns following consecutive daily dosing—an essential milestone for opening the path to patient studies. In parallel, Quantum has signed an agreement with a leading CDMO to manufacture an oral formulation of Lucid-MS as the drug product for its planned Phase 2 clinical trial. The company has also begun preparing key components for an FDA Investigational New Drug (IND) application and submitted Lucid-MS to the UK’s ILAP Passport program, a pathway intended to accelerate access to promising medicines.

Measuring What Matters: Imaging Collaboration with MGH

A frequent obstacle in neuroprotective drug development is proving biological effect. To address this, Quantum is collaborating with Massachusetts General Hospital (MGH) scientists on imaging approaches to monitor myelin integrity. On August 5, 2025, MGH investigators published data in the European Journal of Nuclear Medicine and Molecular Imaging showing that PET tracer [18F]3F4AP exhibited strong brain-imaging properties and could detect differences across MS lesions not visible on conventional MRI. This tracer—developed at MGH and evaluated in healthy controls and people with MS—may serve as a biomarker to track demyelination and treatment response, potentially enhancing the precision of future Lucid-MS efficacy studies.

Pipeline Breadth: Phase 2 Ethics Approval for FSD202 in Australia

Beyond MS, Quantum’s pipeline includes FSD202, which targets nociplastic pain associated with idiopathic Mast Cell Activation Syndrome (MCAS)—a difficult-to-treat presentation of chronic, widespread musculoskeletal pain. In 2025, the company received Human Ethics Review Committee (HERC) approval in Australia for a Phase 2 randomized, double-blind, placebo-controlled trial designed to evaluate safety and efficacy in this population.

Spinout Progress Without Shareholder Dilution

Quantum also created value by spinning out the consumer OTC version of its alcohol-related wellness asset unbuzzd™ to Unbuzzd Wellness Inc. Quantum retains an equity stake (approximately 20% as of mid-2025) and royalty rights of 7% of sales until $250 million is reached, then 3% in perpetuity. In 2025, Unbuzzd launched a Reg D 506(c) capital raise of up to US$5 million to fund growth and a potential go-public path. The company noted this financing does not dilute Quantum BioPharma shareholders. Unbuzzd’s U.S. commercialization continues, with additional regulatory steps underway for Canada.

Strengthening the Balance Sheet

Operational progress has been matched by financial housekeeping. For the quarter ended June 30, 2025, Quantum reported:

  • Current assets of US$10.3 million (up from US$9.9 million at March 31, 2025) and total assets of US$15.3 million (up from US$14.9 million).
  • All debentures converted to equity, removing that liability; previously recorded warrant liability (a non-cash item) was eliminated as all outstanding warrants were exercised by the date of filing.
  • Receipt of a US$2.35 million settlement related to prior management litigation; the Sports Coat litigation loan was fully repaid with full release received.
  • Treasury diversification that includes approximately US$5.5 million of Bitcoin and other cryptocurrencies, with over US$500,000 in realized and unrealized gains as of filing.
  • Management indicated sufficient cash on hand to maintain basic operations beyond March 2027.

During Q2 2025, the share price rose from US$7.71 (March 31) to US$20.25 (June 30), reflecting a period of notable execution across clinical, operational, and financial fronts.

Outlook

Quantum BioPharma enters the next phase with a de-risked safety profile for its lead MS candidate, manufacturing in place for an oral Phase 2 program, and an imaging collaboration that could sharpen efficacy readouts. The company is also advancing FSD202 into a Phase 2 study in Australia and maintaining non-dilutive exposure to a commercializing consumer asset via Unbuzzd. Combined with a cleaner balance sheet and extended cash runway, the setup positions Quantum to pursue upcoming clinical and corporate milestones with focus and flexibility.

All program descriptions reflect company disclosures, published study findings from MGH collaborators, and the most recent financial updates provided by Quantum BioPharma in 2025.

 

Visit $QNTM HUB On AGORACOM : https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

DISCLAIMER AND DISCLOSURE 

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000. 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

Tags: , , ,
Posted in Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma’s Year of Execution: Clinical Momentum, Platform Progress, and a Stronger Balance Sheet

Quantum BioPharma Confronts Extreme Short Pressure Amid Market Imbalances as Borrow Fees Surge Beyond 437%

Posted by Brittany McNabb at 9:55 AM on Friday, June 27th, 2025

Quantum BioPharma (NASDAQ: QNTM / CSE: QNTM) is now facing one of the most severe short pressure environments observed in North American markets this year. The borrow fee on QNTM shares has surged past 437% annually — roughly 1% per trading day — placing it among the highest-cost securities to short across any exchange. These fees signal that brokers are effectively out of lendable inventory and are pricing risk accordingly.

Float Scarcity Driving Volatility Risk

With fewer than 15,000 shares available for borrowing across major prime brokers, QNTM has entered what many refer to as a “locate vacuum.” The company’s public float is approximately 2.6 million shares, making it highly sensitive to buying pressure. In micro-float environments, even small bursts of covering or long-side accumulation can cause rapid price escalation due to a lack of natural sellers and tight liquidity conditions.

Dark Pool Activity Clouds Price Discovery

Adding to concerns is the high proportion of off-exchange short trading. In recent sessions, approximately 59% of QNTM’s daily volume has been routed through dark pools — private trading venues that do not display pre-trade quotes. While such routing is legal, this level of activity can obscure real demand and suppress visible momentum. In an environment where supply is tight and borrow costs are surging, dark pool dominance raises legitimate questions about whether price discovery is functioning as it should.

Echoes of Past Short-Driven Dislocations

The structural setup now surrounding QNTM bears striking similarities to prior market events that resulted in high-profile short squeezes. KaloBios (KBIO) gained over 10,000% in 2015 after its float was effectively locked and borrow availability vanished. GameStop (GME) surged 2,740% in early 2021 under conditions of high borrow fees, float constraints, and elevated short interest. Other comparables include Tilray (TLRY) and KOSS, where borrow fees exceeded 800% during moments of extreme float compression. QNTM’s current borrow rate already exceeds GME’s peak — despite having a much smaller float.

Company Fundamentals Remain Unchanged

While trading volatility has increased, Quantum BioPharma’s operational strategy and clinical programs remain firmly on track. The company recently completed Phase 1 trials for Lucid-MS, a novel treatment designed to repair myelin damage in multiple sclerosis patients. Developed in collaboration with scientists from a Harvard-affiliated teaching hospital, Lucid-MS offers a differentiated approach in a space long dominated by immune suppression therapies. Importantly, the company has made no promotional claims, has not issued new financings, and is not engaged in any stock-related marketing activity.

No Squeeze Assumptions — But Structural Tension Is Clear

A short squeeze is never guaranteed, even with elevated borrow fees and float scarcity. However, the structural tension in QNTM’s trading — characterized by near-zero share availability, high-cost borrow, and dark pool suppression — creates the potential for sudden dislocation if a trigger appears. Any combination of positive news, reduced volume, or insider accumulation could prompt a reflexive covering event in a market ill-equipped to absorb it.

Reaffirming the Need for Market Integrity

Quantum BioPharma has not commented on recent trading behavior but reaffirms its commitment to transparency, scientific advancement, and regulatory compliance. The company supports fair, orderly markets and believes that all participants — including regulators and exchanges — should remain vigilant when structural indicators point to breakdowns in natural price formation. As this situation evolves, investors, analysts, and oversight bodies are encouraged to monitor borrow fees, share availability, and trade routing closely.

Tags: , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, All Recent Posts, Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma Confronts Extreme Short Pressure Amid Market Imbalances as Borrow Fees Surge Beyond 437%

Quantum BioPharma’s $700 Million Lawsuit Highlights Ongoing Concerns Over Market Manipulation

Posted by Brittany McNabb at 3:38 PM on Thursday, May 15th, 2025

The biopharmaceutical company’s legal action against major financial institutions underscores the persistent issue of spoofing in financial markets.

Introduction

Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company focused on developing treatments for neurodegenerative disorders, has filed a lawsuit seeking over $700 million in damages. The legal action alleges that CIBC World Markets and RBC Dominion Securities engaged in market manipulation practices, specifically spoofing, which artificially depressed Quantum’s stock price between January 2020 and August 2024. 

Understanding Spoofing and Its Impact

Spoofing is a deceptive trading practice where traders place large orders with the intent to cancel them before execution, creating a false impression of demand or supply. This manipulates market prices and can mislead other investors. The practice was outlawed under the Dodd-Frank Act in 2010 due to its potential to disrupt market integrity.

In Quantum’s case, the company alleges that such spoofing tactics led to a significant decline in its stock value, which was trading above $460 per share in January 2020. The purported manipulation not only affected the company’s market capitalization but also potentially harmed investors who relied on transparent market operations. 

Legal Proceedings and Representation

Quantum BioPharma has engaged the law firms Christian Attar and Freedman Normand Friedland LLP to represent its case on a contingency basis. This arrangement indicates the legal teams’ confidence in the merits of the case and ensures that Quantum can pursue the lawsuit without immediate financial burden. 

The lawsuit, filed in the U.S. District Court for the Southern District of New York, accuses the defendants of violating multiple sections of the Securities Exchange Act. Quantum has also invited shareholders who believe they were affected by the alleged spoofing to share their experiences, aiming to document the broader impact on investor confidence and market fairness. 

Advancements in Multiple Sclerosis Treatment

Amidst the legal battle, Quantum continues to advance its clinical programs. The company’s lead compound, Lucid-MS, is a first-in-class, non-immunomodulatory, neuroprotective treatment for multiple sclerosis (MS). Unlike traditional MS therapies that suppress the immune system, Lucid-MS aims to protect and restore the myelin sheath surrounding nerve fibers, addressing the root cause of the disease. 

In February 2025, Quantum announced the completion of its Phase 1 clinical trial for Lucid-MS, reporting that the treatment was well-tolerated with no serious adverse events. The company is now preparing to initiate Phase 2 trials, bringing it closer to offering a novel therapeutic option for MS patients.

Conclusion

Quantum BioPharma’s lawsuit against major financial institutions brings to light the ongoing challenges of ensuring market integrity in the face of sophisticated trading manipulations like spoofing. As the company seeks justice through legal channels, it remains committed to its mission of developing innovative treatments for debilitating diseases, exemplified by the progress of Lucid-MS.

Investors and industry observers will be closely monitoring the outcomes of both the legal proceedings and the clinical advancements, as they hold significant implications for market practices and medical breakthroughs alike.

Source: https://corporatefinanceinstitute.com/resources/career-map/sell-side/capital-markets/spoofing/

Visit $QNTM HUB On AGORACOM : https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

DISCLAIMER AND DISCLOSURE 

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000. 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

Tags: , , , , ,
Posted in AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, All Recent Posts, Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma’s $700 Million Lawsuit Highlights Ongoing Concerns Over Market Manipulation

Quantum BioPharma’s Lucid-MS Offers New Hope For Multiple Sclerosis Treatment

Posted by Brittany McNabb at 2:21 PM on Tuesday, April 22nd, 2025

Revolutionizing MS Care: A New Approach Emerges

Multiple sclerosis (MS) affects about 2.8 million people worldwide, causing symptoms like tiredness, difficulty moving, and memory problems. Traditional treatments mainly focus on controlling the immune system to reduce inflammation, but they don’t always address the damage done to the protective covering around nerve fibers, which leads to ongoing disability.

Quantum BioPharma, a company focused on new treatments for brain and nerve diseases, is taking a different approach with Lucid-MS. This new compound aims to protect and even repair the nerve fiber covering, offering a fresh approach to treating MS.

Lucid-MS: A New Treatment Option

Lucid-MS is a patented compound designed to stop and even reverse the damage to the nerve fiber covering, which is a key factor in MS. Unlike current treatments that focus on controlling the immune system, Lucid-MS works to protect and restore the nerve covering without affecting the immune system.

Clinical Milestone: Phase 1 Trial Completed

In February 2025, Quantum BioPharma announced that it successfully completed the first phase of testing Lucid-MS in healthy adults. The trial tested the safety and how the body processes the compound. The results showed no serious side effects, and Lucid-MS was well-tolerated by all participants.

Dr. Andrzej Chruscinski, Vice President of Scientific and Clinical Affairs at Quantum BioPharma, said, “We’re excited that this Phase 1 trial is complete and that Lucid-MS was found to be safe and well-tolerated. This is an important step forward and sets the stage for the next phase of development.”

Moving to Phase 2: Targeting MS Patients

Now that Phase 1 is complete, Quantum BioPharma is getting ready to start Phase 2 trials to test Lucid-MS in people with MS. This phase will focus on seeing if Lucid-MS can slow or stop the damage to the nerve covering in people with MS.

CEO Zeeshan Saeed shared his excitement: “We’re very hopeful that Lucid-MS can protect the nerve covering in MS patients, which represents a new approach to treating the disease. With Phase 1 complete and the safety confirmed, we’re now ready to move on to testing it in MS patients.”

Working Together: Improving MS Diagnosis

Along with developing Lucid-MS, Quantum BioPharma is working with scientists at Massachusetts General Hospital to test a new imaging technique. This advanced scan will help doctors see the condition of the nerve covering in MS patients, giving a better way to track the disease and see how well treatments are working.

Conclusion: A Bright Future for MS Treatment

Quantum BioPharma’s work with Lucid-MS could change the way MS is treated by focusing on protecting and repairing nerve fibers, rather than just controlling the immune system. As they move forward with Phase 2 trials, both doctors and patients are eagerly awaiting what comes next.

For more information on Quantum BioPharma and Lucid-MS, please visit www.quantumbiopharma.com.

Source: https://www.ninds.nih.gov/health-information/disorders/multiple-sclerosis

YOUR NEXT STEPS 

Visit $QNTM HUB On AGORACOM: https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

Watch $QNTM Videos On AGORACOM YouTube Channel:

https://studio.youtube.com/playlist/PLfL457LW0vdK6S1r-_VHqbuWQNDV4fV-D/videos

DISCLAIMER AND DISCLOSURE 

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000. 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

Tags: , , , ,
Posted in AGORACOM Client Feature, AGORACOM Small Cap Stocks For Investment, AGORACOM Traffic, All Recent Posts, Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma’s Lucid-MS Offers New Hope For Multiple Sclerosis Treatment

Quantum BioPharma’s Secret Weapon: A Dual Engine of Clinical Innovation and Consumer Expansion

Posted by Brittany McNabb at 11:10 AM on Wednesday, April 16th, 2025

From clinical breakthroughs in multiple sclerosis to a fast-growing alcohol detox brand, Quantum BioPharma is bridging biotech innovation with real-world impact.

A Biopharma Platform Tackling Today’s Toughest Health Challenges

Quantum BioPharma Ltd. (NASDAQ: QNTM | CSE: QNTM) is emerging as a dynamic force in the biotechnology sector, developing solutions for two major public health issues: neurodegenerative diseases and alcohol misuse. With a diversified pipeline spanning prescription drugs and over-the-counter consumer products, the company is building an integrated portfolio capable of delivering both near-term commercial gains and long-term medical breakthroughs.

The company’s strategy is uniquely positioned at the intersection of science, innovation, and unmet need — making it one of the few small-cap biotechs advancing both FDA-bound therapeutics and consumer-ready wellness products simultaneously.

Lucid-MS: Targeting the Root Cause of Multiple Sclerosis

At the heart of Quantum’s pharmaceutical program is Lucid-MS, a patented new chemical entity showing early promise in treating multiple sclerosis (MS). Unlike conventional MS drugs that focus on managing inflammation, Lucid-MS addresses the core driver of long-term disability in MS: the breakdown of the myelin sheath — the protective layer around nerve fibers.

Following a successful Phase 1 clinical trial, the drug has been deemed safe and well-tolerated, with therapeutic blood levels observed in healthy participants. Quantum is now preparing to launch a Phase 2 trial in 2026, targeting efficacy in MS patients.

What makes Lucid-MS even more distinctive is Quantum’s collaborative study with Massachusetts General Hospital (MGH), featuring scientists from Harvard Medical School, to validate advanced PET imaging as a way to monitor demyelination in real time. This partnership elevates both the scientific credibility and clinical precision behind Lucid-MS, positioning it as a next-generation therapeutic candidate in a $27 billion global MS treatment market.

unbuzzd™: A Consumer Wellness Product with Scientific Backing

In parallel with its clinical pipeline, Quantum BioPharma is making significant inroads in the consumer wellness market through unbuzzd™, an over-the-counter alcohol detox and recovery beverage developed by its spinout, Celly Nutrition Corp. The product, a fast-acting powder stick formulated by pharmacology experts, is designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms.

unbuzzd™ is already making retail waves. Backed by a double-blind, placebo-controlled clinical trial, the beverage demonstrated that it could reduce blood alcohol concentration (BAC) over 40% faster than placebo in many subjects. It’s now available via Amazon and unbuzzd.com, with retail expansion underway in the U.S., Puerto Rico, and the Caribbean through a new distribution agreement with FUSION Distribution Group.

Most recently, unbuzzd™ entered a landmark partnership with AATAC, one of the largest retail networks in the U.S., which connects the product to over 80,000 convenience store locations. This expansion gives unbuzzd™ exposure to leading chains like 7-Eleven, Circle K, Shell, and ampm — significantly scaling its retail footprint.

Multiple Value Streams, One Vision

Quantum BioPharma holds 25.71% ownership in Celly Nutrition and receives up to 7% in royalties from unbuzzd™ sales until a $250M threshold is met — and 3% in perpetuity thereafter. This structure offers upside exposure to the high-growth consumer market while maintaining strategic focus on the pharmaceutical pipeline.

With an improved cash position, enhanced operational efficiency, and momentum across both drug development and consumer wellness fronts, the company is now advancing toward key inflection points on multiple fronts.

A Biotech Story Worth Watching

With a first-in-class MS treatment advancing toward Phase 2 trials, a consumer product already on shelves and gaining market traction, and elite partnerships with global institutions like Harvard and AATAC — Quantum BioPharma stands apart in the small-cap biotech landscape.

It’s not just a company developing drugs. It’s building a platform for impact, backed by scientific validation and commercial momentum.


YOUR NEXT STEPS 

Visit $QNTM HUB On AGORACOM: https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

Watch $QNTM Videos On AGORACOM YouTube Channel:

https://studio.youtube.com/playlist/PLfL457LW0vdK6S1r-_VHqbuWQNDV4fV-D/videos

DISCLAIMER AND DISCLOSURE 

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000. 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

Tags: , , , , , , , ,
Posted in Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma’s Secret Weapon: A Dual Engine of Clinical Innovation and Consumer Expansion

Canadian Biotech Quantum BioPharma Nears a Landmark Multiple Sclerosis Breakthrough

Posted by Brittany McNabb at 9:54 AM on Thursday, March 27th, 2025

New Approach Could Redefine How Multiple Sclerosis Is Treated Worldwide

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) may be on the verge of redefining treatment for multiple sclerosis (MS), a chronic neurological disorder affecting nearly 3 million people worldwide. In a compelling interview on the AGORACOM, Dr. Andrzej Chruscinski, Vice-President of Scientific and Clinical Affairs at Quantum BioPharma, detailed the company’s successful completion of its Phase 1 clinical trial for Lucid-MS, a first-in-class neuroprotective drug targeting demyelination—the core driver of MS progression.

Unlike existing treatments, which primarily focus on managing the immune system and controlling inflammation, Lucid-MS takes aim at protecting and potentially repairing the myelin sheath—the protective layer around nerve cells that degenerates in MS patients. “We’re excited about the potential of Lucid-MS to protect myelin in MS patients as it represents a new direction in the treatment of this disease,” said Quantum BioPharma CEO Zeeshan Saeed.

A Novel Solution to a Persistent Problem

Most MS therapies today only address the inflammatory aspect of the disease, leaving the underlying neurodegeneration largely unaddressed. Lucid-MS changes that narrative.

  • The drug works by preventing the unraveling of the myelin sheath, a process triggered by a chemical modification known as citrullination.

  • Developed over a decade by Dr. Lakshmi Kotra and Dr. Mario Moscarello at the University of Toronto, Lucid-MS targets this key process, aiming to halt disease progression and protect nerve communication.

  • The approach has already shown success in preclinical animal models.

“Think of the myelin sheath like insulation around electrical wiring. When that’s compromised, signals can’t transmit properly,” explained Dr. Chruscinski. “Our drug preserves that insulation, maintaining neural function.”

Phase 1 Trial: Safety Confirmed, Therapeutic Potential Emerges

The recently completed Phase 1 trial focused on evaluating safety and pharmacokinetics in healthy participants. According to Dr. Chruscinski, “Lucid-MS was safe and well-tolerated, with no adverse events. We’re also pleased with the drug levels observed in blood, which we believe are therapeutic.”

This milestone is crucial for advancing to Phase 2, where the company will begin testing Lucid-MS in MS patients to assess efficacy.

What to Expect in Phase 2

The company is actively designing its Phase 2 trial with a projected start in Q1 2026, pending FDA clearance via an Investigational New Drug (IND) application in late 2025.

Key details under consideration:

  • The trial will include roughly 60 MS patients (30 receiving Lucid-MS and 30 on placebo).

  • Outcomes will be measured using MRI scans and clinical assessments to evaluate both biological and functional improvement.

  • While the exact location is yet to be confirmed, Quantum is exploring options to include Canadian sites in recognition of the drug’s Canadian origins.

Support From the Scientific Community

Feedback from global experts at major MS conferences in North America and Europe has been overwhelmingly positive. “The response has been tremendous,” said Dr. Chruscinski. “There’s a real appetite for a drug that targets neurodegeneration, which remains an unmet need in MS.”

This third-party validation underscores the broader scientific and commercial relevance of Quantum BioPharma’s work.

A Human-Centered Mission With Investor Appeal

Dr. Chruscinski also emphasized his personal motivation. “It’s exciting to be part of something that could make a real difference. I was there when the first dose was administered in our Phase 1 trial. That’s a moment I won’t forget.”

While the drug development process remains long and complex, Quantum BioPharma has achieved a significant milestone that positions the company—and Lucid-MS—at the forefront of innovation in MS treatment.

For investors, the opportunity lies in Quantum’s unique approach, successful early data, and a clearly defined path toward a potential market-shifting solution.

Conclusion: A Meaningful Milestone With a Promising Horizon

With a Phase 1 trial successfully completed and a novel therapeutic mechanism unlike anything currently on the market, Quantum BioPharma is emerging as a company to watch in the fight against multiple sclerosis. As it gears up for its Phase 2 trial and FDA engagement, the company stands at a pivotal inflection point—one that could not only deliver long-term value for investors but also reshape the future of MS care.

To hear Dr. Chruscinski explain the science, milestones, and next steps in his own words, watch the full interview here: 

Tags: , , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, AGORACOM Via Satellite, All Recent Posts, Quantum BioPharma Ltd. | Comments Off on Canadian Biotech Quantum BioPharma Nears a Landmark Multiple Sclerosis Breakthrough

Canadian Small Cap Quantum BioPharma on The Verge of Multiple Sclerosis Breakthrough

Posted by Brittany McNabb at 5:01 PM on Tuesday, March 25th, 2025

KEY MILESTONES AND WHAT’S NEXT

  • Successful Phase 1 Trial: Lucid-MS has shown excellent safety with no serious side effects, paving the way for a groundbreaking treatment for MS.
  • Next Major Step: The Phase 2 trial is set for early 2026, with 60 participants.
  • FDA Submission on the Horizon: Plans to submit application to the FDA by late 2025, taking a huge step toward regulatory approval.
  • Massive Market Opportunity: With 2.9 million people worldwide affected by Multiple Sclerosis and the market projected to surpass $30 billion by 2030, Lucid-MS could potentially capture a significant share of this rapidly expanding space.

A NEW ERA IN MULTIPLE SCLEROSIS TREATMENT

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Lucid-MS is setting the stage to revolutionize MS treatment. Unlike existing therapies that only target immune system responses, Lucid-MS focuses on protecting and repairing myelin, the critical layer around nerve fibers. This novel approach has the potential to slow or even reverse disease progression—offering new hope for millions of MS sufferers.

HOW DOES IT WORK? A TOTALLY NEW APPROACH TO TREATING MS

Think of nerves like electrical wires in your body, and myelin as the protective coating around those wires. With Multiple Sclerosis, the immune system attacks this coating (called demyelination), causing damage that leads to muscle weakness, vision problems, and difficulty moving.

Most MS treatments try to calm the immune system to slow down the attack. Lucid-MS is different. Instead of focusing on the immune system, it works directly on the myelin to stabilize and protect it from damage.

WHY IS THIS IMPORTANT?

By keeping myelin intact, Lucid-MS may help slow down the progression of MS and prevent disability—something current MS drugs don’t do very well.

SCIENTIFIC BREAKTHROUGH BACKED BY INDUSTRY RECOGNITION

Lucid-MS is backed by cutting-edge research from Dr. Lakshmi Khotra’s lab at the University of Toronto, where the critical process of myelin breakdown in MS patients was discovered. The drug’s ability to address this underlying issue is a potential game-changer in neurodegenerative treatments.

It’s already gaining enthusiastic support from leading medical experts and researchers, underscoring its transformative potential.

A VISION FOR THE FUTURE

Dr. Andrzej Chruscinski, Vice President of Scientific and Clinical Affairs at Quantum BioPharma, expressed the company’s excitement about Lucid-MS’s future.

“We are on the cusp of something monumental. Lucid-MS has the potential to transform MS treatment and open doors for treating other nerve-related diseases. As we move toward Phase 2 and beyond, we’re excited to bring this innovative therapy to the patients who need it most.”

With promising clinical results, a massive market opportunity, and rising industry recognition, Quantum BioPharma is leading the charge in next-generation treatments for Multiple Sclerosis 

YOUR NEXT $QNTM STEPS

$QNTM HUB On AGORACOM: https://agoracom.com/ir/Quantumbiopharma $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopha… $QNTM Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/Quantumbiopha… Connect With AGORACOM Anyway You Like AGORACOM Website: https://www.agoracom.com – The Most Trusted Source Of Small Cap Information AGORACOM YouTube: Hit That Subscribe Button Right Now For More Powerful Videos AGORACOM X: https://www.x.com/AGORACOM Verified Top 0.2% Account AGORACOM Spotify: https://open.spotify.com/show/74mVPkf… Planes, Trains, Automobiles & Walking The Dog AGORACOM

Tags: , , , , ,
Posted in AGORACOM Via Satellite, Quantum BioPharma Ltd. | Comments Off on Canadian Small Cap Quantum BioPharma on The Verge of Multiple Sclerosis Breakthrough

« Older Entries